KLHL33: A Potential Drug Target and Biomarker (G123103)

Target Name: KLHL33

NCBI ID: G123103

KLHL33

KLHL33: A Potential Drug Target and Biomarker

Klinefelter leukemia (KL) is a type of cancer that affects the white blood cells, particularly leukemia cells. It is characterized by the production of too many white blood cells, which can lead to a variety of health problems, including anemia, infections, and damage to the heart. KL is a hereditary disease that is caused by changes in the chromosomes, and it is typically inherited from one's parents.

KLHL33 is a gene that has been identified as a potential drug target and biomarker for the treatment of KL. The gene is located on chromosome 18 and encodes a protein known as KLHL33. KLHL33 is a 21-kDa protein that is expressed in various tissues and cells, including blood cells, tissue cells, and the nervous system.

KLHL33 is involved in the regulation of cell growth and division, and it has been shown to play a role in the development and progression of various types of cancer. Studies have suggested that KLHL33 may be a potential drug target because it is involved in the regulation of cell proliferation and has been shown to interact with a variety of signaling pathways, including TGF-β, NF-kappa-B, and PI3K.

In addition to its potential as a drug target, KLHL33 has also been shown to be a potential biomarker for the diagnosis and monitoring of KL. Studies have shown that KLHL33 levels can be accurately measured in KL samples and that they are closely correlated with the severity of KL disease. This suggests that KLHL33 could be used as a biomarker for the evaluation of KL patients, including those undergoing treatment.

Overall, the potential drug target and biomarker properties of KLHL33 make it an intriguing candidate for further research and development as a treatment for KL. Further studies are needed to fully understand its role in the treatment of KL and to determine its potential as a biomarker for this disease.

Protein Name: Kelch Like Family Member 33

The "KLHL33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHL33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets